Accès libre

MICB Genetic Variants and Its Protein Soluble Level Are Associated with the Risk of Chronic GvHD and CMV Infection after Allogeneic HSCT

Jagoda Siemaszko
Jagoda Siemaszko
, 
Marta Dratwa
Marta Dratwa
, 
Agnieszka Szeremet
Agnieszka Szeremet
, 
Maciej Majcherek
Maciej Majcherek
, 
Anna Czyż
Anna Czyż
, 
Małgorzata Sobczyk-Kruszelnicka
Małgorzata Sobczyk-Kruszelnicka
, 
Wojciech Fidyk
Wojciech Fidyk
, 
Iwona Solarska
Iwona Solarska
, 
Barbara Nasiłowska-Adamska
Barbara Nasiłowska-Adamska
, 
Patrycja Skowrońska
Patrycja Skowrońska
, 
Maria Bieniaszewska
Maria Bieniaszewska
, 
Agnieszka Tomaszewska
Agnieszka Tomaszewska
, 
Grzegorz W. Basak
Grzegorz W. Basak
, 
Sebastian Giebel
Sebastian Giebel
, 
Tomasz Wróbel
Tomasz Wróbel
 et 
Katarzyna Bogunia-Kubik
Katarzyna Bogunia-Kubik
   | 07 juin 2024
Archivum Immunologiae et Therapiae Experimentalis's Cover Image
À propos de cet article
Article précédent
Article suivant
Citez
Article Category: Original Article
Publié en ligne: 07 juin 2024
Pages: -
Reçu: 20 févr. 2024
Accepté: 13 mai 2024
DOI: https://doi.org/10.2478/aite-2024-0012
Mots clés
© 2024 Jagoda Siemaszko et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Fig 1.

MICB genetic variants and development of cGvHD. (a) Donor rs1065056 G allele was less common among patients who developed cGvHD. (b) Donor rs3828903 G allele was more prevalent among recipients lacking cGvHD post-transplantation. cGvHD, chronic graft-versus-host disease; HSCT, hematopoietic stem cell transplantation.
MICB genetic variants and development of cGvHD. (a) Donor rs1065056 G allele was less common among patients who developed cGvHD. (b) Donor rs3828903 G allele was more prevalent among recipients lacking cGvHD post-transplantation. cGvHD, chronic graft-versus-host disease; HSCT, hematopoietic stem cell transplantation.

Fig 2.

Associations between the MICB genotype and the risk of CMV infection development. (a) CMV infection was less frequent in recipients carrying the rs1065075 G allele. (b) Lower incidence of CMV infection in patients transplanted from donors with rs1065075 G allele. CMV, cytomegalovirus; HSCT, hematopoietic stem cell transplantation.
Associations between the MICB genotype and the risk of CMV infection development. (a) CMV infection was less frequent in recipients carrying the rs1065075 G allele. (b) Lower incidence of CMV infection in patients transplanted from donors with rs1065075 G allele. CMV, cytomegalovirus; HSCT, hematopoietic stem cell transplantation.

Fig 3.

Serum sMICB levels in recipients diagnosed with various post-transplant complications. (a) Increased sMICB concentration in recipients with CMV infection. (b) Higher sMICB level in patients who developed chronic form of GvHD. cGvHD, chronic graft-versus-host disease; CMV, cytomegalovirus; GvHD, graft-versus-host-disease; sMICB, soluble MICB.
Serum sMICB levels in recipients diagnosed with various post-transplant complications. (a) Increased sMICB concentration in recipients with CMV infection. (b) Higher sMICB level in patients who developed chronic form of GvHD. cGvHD, chronic graft-versus-host disease; CMV, cytomegalovirus; GvHD, graft-versus-host-disease; sMICB, soluble MICB.

Fig 4.

Relationships between serum sMICB and two MICB SNPs. (a) Lower sMICB level in serum samples of MICB rs1065057 GG homozygous patients. (b) Differences in sMICB concentration between recipients carrying various MICB rs3828903 genotypes. sMICB, soluble MICB; SNPs, single nucleotide polymorphism.
Relationships between serum sMICB and two MICB SNPs. (a) Lower sMICB level in serum samples of MICB rs1065057 GG homozygous patients. (b) Differences in sMICB concentration between recipients carrying various MICB rs3828903 genotypes. sMICB, soluble MICB; SNPs, single nucleotide polymorphism.

Results of the multivariate analysis for CMV risk factors

Variables P value OR 95% CI
Age 0.5988 0.9937 0.9702–1.0176
D/R HLA compatibility 0.0142 0.4276 0.2144–0.8385
Recipient CMV IgG status <0.0001 16.2592 4.8663–76.9165
Donor CMV IgG status 0.1884 0.5834 0.2570–1.2944
Donor sex 0.1606 1.6562 0.8250–3.3949
MICB rs1065057 G allele 0.0238 0.4701 0.2417–0.8988

Serum sMICB concentrations in HSCT recipients

No CMV (pg/mL) CMV [pg/mL] No cGvHD (pg/mL) cGvHD (pg/mL)
Mean 67.13 96.85 62.47 116.2
SD 54.23 72.04 49.88 77.03
Std. Error 8.47 12.18 6.73 15.72
25–75% percentile 25.38–94.86 39.42–129.8 26.53–88.25 71.60–145.2
95% CI 50.01–84.25 72.10–121.6 48.98–75.95 83.69–148.7

Patients' characteristics

N = 232
Age (years, median, range) 50, 18–73
Sex (M/F) 135 (58.19%)/97 (41.81%)
Type of donor
  MSD 107 (46.12%)
  MUD 54 (23.28%)
Haploidentical 53 (22.84%)
MMSD 17 (7.33%)
Diagnosis
  AML 92 (39.66%)
  ALL 29 (14.50%)
  MDS 25 (12.50%)
  NHL 18 (9%)
  MPN 17 (8.50%)
  HL 10 (5%)
  PCM 8 (4%)
  Other 33 (16.50%)
Conditioning
  RIC/MAC/NMA 104 (44.83%)/125 (53.88%)/3 (1.29%)
Post-transplant complications
  aGvHD (I–IV) 91 (39.22%)
  aGvHD (II–IV) 48 (20.69%)
  cGvHD 46 (19.83%)
  cGvHD de novo/progression of aGvHD to cGvHD/after aGvHD remission 17 (36.96%)/8 (17.39%)/20 (43.48%)
  CMV 90 (38.79%)
  Relapse 31 (13.36%)
  Death 30 (12.93%)
No complicationsa 83 (35.78%)

Mean serum sMICB concentrations of patients with various MICB genotypes

MICB SNP
Variant rs1065057 rs3828903
AA 91.47 pg/mL 90.45 pg/mL
AG 74.95 pg/mL 90.48 pg/mL
GG 39.78 pg/mL 63.49 pg/mL
eISSN:
1661-4917
Langue:
Anglais
Périodicité:
Volume Open
Sujets de la revue:
Medicine, Basic Medical Science, Biochemistry, Immunology, Clinical Medicine, other, Clinical Chemistry
RSS Feed de la revue